Literature DB >> 21062751

The epigenomic interface between genome and environment in common complex diseases.

Christopher G Bell1, Stephan Beck.   

Abstract

The epigenome plays the pivotal role as interface between genome and environment. True genome-wide assessments of epigenetic marks, such as DNA methylation (methylomes) or chromatin modifications (chromatinomes), are now possible, either through high-throughput arrays or increasingly by second-generation DNA sequencing methods. The ability to collect these data at this level of resolution enables us to begin to be able to propose detailed questions, and interrogate this information, with regards to changes that occur due to development, lineage and tissue-specificity, and significantly those caused by environmental influence, such as ageing, stress, diet, hormones or toxins. Common complex traits are under variable levels of genetic influence and additionally epigenetic effect. The detection of pathological epigenetic alterations will reveal additional insights into their aetiology and how possible environmental modulation of this mechanism may occur. Due to the reversibility of these marks, the potential for sequence-specific targeted therapeutics exists. This review surveys recent epigenomic advances and their current and prospective application to the study of common diseases.

Mesh:

Year:  2010        PMID: 21062751      PMCID: PMC3080746          DOI: 10.1093/bfgp/elq026

Source DB:  PubMed          Journal:  Brief Funct Genomics        ISSN: 2041-2649            Impact factor:   4.241


  79 in total

Review 1.  DNA methylation and human disease.

Authors:  Keith D Robertson
Journal:  Nat Rev Genet       Date:  2005-08       Impact factor: 53.242

Review 2.  Phenotypic plasticity and the epigenetics of human disease.

Authors:  Andrew P Feinberg
Journal:  Nature       Date:  2007-05-24       Impact factor: 49.962

3.  Heritable gene repression through the action of a directed DNA methyltransferase at a chromosomal locus.

Authors:  Alexander E Smith; Paul J Hurd; Andrew J Bannister; Tony Kouzarides; Kevin G Ford
Journal:  J Biol Chem       Date:  2008-02-13       Impact factor: 5.157

4.  Methylation and deamination of CpGs generate p53-binding sites on a genomic scale.

Authors:  Tomasz Zemojtel; Szymon M Kielbasa; Peter F Arndt; Ho-Ryun Chung; Martin Vingron
Journal:  Trends Genet       Date:  2008-12-26       Impact factor: 11.639

5.  The saving switch.

Authors:  Cassandra Willyard
Journal:  Nat Med       Date:  2010-01       Impact factor: 53.440

6.  Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a.

Authors:  B H Ramsahoye; D Biniszkiewicz; F Lyko; V Clark; A P Bird; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

7.  Induction of DNA hypomethylation by tumor hypoxia.

Authors:  Siranoush Shahrzad; Kelsey Bertrand; Kanwal Minhas; Brenda L Coomber
Journal:  Epigenetics       Date:  2007-06-14       Impact factor: 4.528

8.  Constructing genomic maps of positive selection in humans: where do we go from here?

Authors:  Joshua M Akey
Journal:  Genome Res       Date:  2009-05       Impact factor: 9.043

9.  DNA methylation profiling of human chromosomes 6, 20 and 22.

Authors:  Florian Eckhardt; Joern Lewin; Rene Cortese; Vardhman K Rakyan; John Attwood; Matthias Burger; John Burton; Tony V Cox; Rob Davies; Thomas A Down; Carolina Haefliger; Roger Horton; Kevin Howe; David K Jackson; Jan Kunde; Christoph Koenig; Jennifer Liddle; David Niblett; Thomas Otto; Roger Pettett; Stefanie Seemann; Christian Thompson; Tony West; Jane Rogers; Alex Olek; Kurt Berlin; Stephan Beck
Journal:  Nat Genet       Date:  2006-10-29       Impact factor: 38.330

10.  Mutation patterns in the human genome: more variable than expected.

Authors:  Laurent Duret
Journal:  PLoS Biol       Date:  2009-02-03       Impact factor: 8.029

View more
  21 in total

1.  [Computer experience and further developments in the respiratory function laboratory (author's transl)].

Authors:  R Schindl; K Mayer; K Aigner
Journal:  Med Klin       Date:  1975-11-07

Review 2.  Epigenetics, epidemiology and mitochondrial DNA diseases.

Authors:  Patrick F Chinnery; Hannah R Elliott; Gavin Hudson; David C Samuels; Caroline L Relton
Journal:  Int J Epidemiol       Date:  2012-01-28       Impact factor: 7.196

3.  The decade of the epigenomes?

Authors:  Joost H A Martens; Hendrik G Stunnenberg; Colin Logie
Journal:  Genes Cancer       Date:  2011-06

Review 4.  Epigenetics and the transition from acute to chronic pain.

Authors:  Thomas Buchheit; Thomas Van de Ven; Andrew Shaw
Journal:  Pain Med       Date:  2012-09-14       Impact factor: 3.750

Review 5.  Epigenetic alterations in autoimmune rheumatic diseases.

Authors:  Esteban Ballestar
Journal:  Nat Rev Rheumatol       Date:  2011-02-22       Impact factor: 20.543

6.  Epigenetics and microRNAs in preeclampsia.

Authors:  Mahua Choudhury; Jacob E Friedman
Journal:  Clin Exp Hypertens       Date:  2012-04-02       Impact factor: 1.749

Review 7.  Epigenetic mechanisms in commonly occurring cancers.

Authors:  Lauren P Blair; Qin Yan
Journal:  DNA Cell Biol       Date:  2012-04-20       Impact factor: 3.311

8.  Transgenerational latent early-life associated regulation unites environment and genetics across generations.

Authors:  Debomoy K Lahiri; Bryan Maloney; Baindu L Bayon; Nipun Chopra; Fletcher A White; Nigel H Greig; John I Nurnberger
Journal:  Epigenomics       Date:  2016-03-07       Impact factor: 4.778

9.  Gene × environment interaction by a longitudinal epigenome-wide association study (LEWAS) overcomes limitations of genome-wide association study (GWAS).

Authors:  Debomoy K Lahiri; Bryan Maloney
Journal:  Epigenomics       Date:  2012-12       Impact factor: 4.778

10.  Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma.

Authors:  Maribel Botana-Rial; Loretta De Chiara; Diana Valverde; Virginia Leiro-Fernández; Cristina Represas-Represas; Victor Del Campo-Pérez; Alberto Fernández-Villar
Journal:  Cancer Biol Ther       Date:  2012-09-06       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.